Other Species / Isoforms
  K12 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S22-p
PGLSRRLsSQSVIGR
0 1
K12 (human) PGLSRRLsSQSVIGR S22-p
K12 (mouse) SALSRRSSSQNGAAG S15
K12 (rat) SALSRRSSSQNGVAG S15
S138-p
NLNDRLAsyLDkVRA
0 6
K12 (human) NLNDRLAsyLDkVRA S138-p
K12 (mouse) NLNDRLASYLGKVRS S132
K12 (rat) NLNDRLASYLGKVRA S128
Y139-p
LNDRLAsyLDkVRAL
0 77
K12 (human) LNDRLAsyLDkVRAL Y139-p
K12 (mouse) LNDRLASYLGKVRSL Y133
K12 (rat) LNDRLASYLGKVRAL Y129
K142-ub
RLAsyLDkVRALEEA
0 8
K12 (human) RLAsyLDkVRALEEA K142-ub
K12 (mouse) RLASYLGKVRSLEEA K136
K12 (rat) RLASYLGKVRALEEA K132
Y161-p
ENKIREWyEtRGTGT
0 1
K12 (human) ENKIREWyEtRGTGT Y161-p
K12 (mouse) ENKIREWYETRRTRD Y155
K12 (rat) ENKIREWYETRRTGD Y151
T163-p
KIREWyEtRGTGTAD
0 1
K12 (human) KIREWyEtRGTGTAD T163-p
K12 (mouse) KIREWYETRRTRDAG T157
K12 (rat) KIREWYETRRTGDSG T153
K189-ub
LIEDLRNkIISASIG
Upstream
Downstream
0 1
Effects on Modified Protein
  • protein degradation
Treatment
  • bortezomib
K12 (human) LIEDLRNkIISASIG K189-ub
K12 (mouse) LIEDLKNKIVSARVS K182
K12 (rat) LIEDLKNKIISASVS K178
Y262-p
SLNEELAyMKKNHED
0 1
K12 (human) SLNEELAyMKKNHED Y262-p
K12 (mouse) TLTEELAYMKKNHEE Y255
K12 (rat) NLTEELAYMKKNHEE Y251
Y429-p
LELEIETyRRLLDGE
0 2
K12 (human) LELEIETyRRLLDGE Y429-p
K12 (mouse) LEMEIETYRRLLEGD Y422
K12 (rat) LEMEIETYRRLLEGD Y391